Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Severity of adverse reactions is associated with T-cell response in mRNA-1273 vaccinated health care workers

  • Hanna Klingel (Laboratory Diagnostic Center, University Hospital RWTH Aachen) ;
  • Maike Lauen (Laboratory Diagnostic Center, University Hospital RWTH Aachen) ;
  • Alexander Kruttgen (Laboratory Diagnostic Center, University Hospital RWTH Aachen) ;
  • Matthias Imohl (Laboratory Diagnostic Center, University Hospital RWTH Aachen) ;
  • Michael Kleines (Laboratory Diagnostic Center, University Hospital RWTH Aachen)
  • Received : 2021.10.08
  • Accepted : 2021.10.24
  • Published : 2022.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Knowledge about mRNA-1273 elicited T-cell response is limited. We investigated adverse reactions and interferon gamma release by specific T-cells among mRNA-1273 vaccinated health care workers. Seven to 13 weeks after complete vaccination low levels of specific T-cells were detected not correlating with antibody response. Severity of symptoms after first and number of symptoms after second immunization were associated with T-cell response. Assessment of T-cell response in addition to antibody response is crucial because even few specific T-cells could add to protection against infection. Investigation of mRNA-1273 induced inflammatory processes might help improve reactogenicity and immunogenicity.

Keywords

References

  1. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020;396:1595-606.
  2. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med 2020;383:1920-31.
  3. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: the COVID-19 case. J Control Release 2021;333:511-20.
  4. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19. N Engl J Med 2021;384:2259-61.
  5. Sahin U, Muik A, Derhovanessian E, et al. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. MedRxiv [Preprint] 2020 Jan 1 [Epub]. https://doi.org/10.1101/2020.07.17.20140533.
  6. Angyal A, Longet S, Moore SC, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe 2021 Nov 9 [Epub]. https://doi.org/10.1016/S2666-5247(21)00275-5.
  7. Martinez-Gallo M, Esperalba-Ezquerra J, Pujol-Borrell R, et al. Commercialized kit to assess T-cell responses against SARS-CoV-2 S peptides: a pilot study in health care workers. medRxiv [Preprint] 2021 Jan 1 [Epub]. https://doi.org/10.1101/2021.03.31.21254472.
  8. Goel RR, Apostolidis SA, Painter MM, et al. Longitudinal analysis reveals distinct antibody and memory B cell responses in SARS-CoV2 naive and recovered individuals following mRNA vaccination. medRxiv [Preprint] 2021 Mar 6 [Epub]. https://doi.org/10.1101/2021.03.03.21252872.
  9. Kruttgen A, Cornelissen CG, Dreher M, Hornef MW, Imohl M, Kleines M. Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet. J Virol Methods 2021;287:113978.
  10. Meyer B, Reimerink J, Torriani G, et al. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg Microbes Infect 2020;9:2394-403.
  11. Van Praet JT, Vandecasteele S, De Roo A, De Vriese AS, Reynders M. Humoral and cellular immunogenicity of the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in nursing home residents. Clin Infect Dis 2021;73:2145-7.
  12. Schwarz T, Tober-Lau P, Hillus D, et al. Delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany. Emerg Infect Dis 2021;27:2174-8.
  13. Rauch S, Gooch KE, Hall Y, et al. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. Biorxiv [Preprint] 2020 Jan 1 [Epub]. https://doi.org/10.1101/2020.12.23.424138.
  14. Neidleman J, Luo X, McGregor M, et al. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. bioRxiv [Preprint] 2021 Jul 29 [Epub]. https://doi.org/10.1101/2021.05.12.443888.
  15. Cagigi A, Lore K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines (Basel) 2021;9:61.
  16. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590:630-4.
  17. Ivanova EN, Devlin JC, Buus TB, et al. SARS-CoV-2 mRNA vaccine elicits a potent adaptive immune response in the absence of IFN-mediated inflammation observed in COVID-19. medRxiv [Preprint] 2021 Apr 21 [Epub]. https://doi.org/10.1101/2021.04.20.21255677.
  18. Pulendran B, Arunachalam PS. Systems biological assessment of human immunity to BNT162b2 mRNA vaccination. Res Sq [Preprint] 2021 Apr 22 [Epub]. https://doi.org/10.21203/rs.3.rs-438662/v1.